Avandia (Rosiglitazone) Lowers Markers for Cardiovascular Inflammation in Diabetic Patients
SAN FRANCISCO, CA — June 17, 2002 — Avandia® (rosiglitazone) appears to lower markers of cardiovascular inflammation — a precursor of atherosclerosis and heart disease
